Evaluation of Clinical Effectiveness and Safety of Lenampicillin in Acute Tonsillitis

In Comparison with Cefaclor by Double-blind Method

Abstract

A double blind study has been carried out for the effectiveness, safety and usefulness of Lenampicillin (LAPC, 250 mg, t. i. d.) for acute tonsillitis. 1. For all the rate of effectiveness (excellent+good) just evaluated by a physician in charge with LAPC group 91.1 % (82/90) and Cefaclor (CCL) group 83.9 % (78/93), and by Committee judgement with LAPC group 78.9 % (71/90) and CCL group 72.0 % (67/93), no significant difference was found despite LAPC group being in fact higher in effectiveness. 2. In the bacteriological effect, no significant difference was recognized with almost the same eradication rate between LAPC group 97.6 % and CCL group 98.8 %. 3. In regard to the safety, no significant difference in the cases of appearance of side effects has been recognized with LAPC group, 6 cases out of 128 (4.7 %), and CCL group, 6 cases out of 126 (4.8 96). 4. As for the usefulness, no significant difference was recognized with the rate of usefulness (markedly satisfactory +satisfactory), LAPC group 87.0 % (80/92) and CCL group 84.5 96 (82/97). From the results thus obtained above, the LAPC (250 mg, t. i. d.) can be considered as highly useful drug being capable of expecting the same result when compared with CCL (250 mg, t. i. d.) for the treatment of acute tonsillitis.